Seroprevalence of hepatitis C virus antigen in patients with chronic liver disease and hepatocellular carcinoma at 12 week of treatment: a cross-sectional study.

Introduction: epidemiological data suggests that more than 50% of hepatitis C virus (HCV) patients fail treatment. The objective of the study was to highlight the seroprevalence of hepatitis C virus antigen (HCV Ag) at the 12 week of treatment.

Methods: during a cross-sectional study, participants with chronic liver disease and hepatocellular carcinoma (HCC) were recruited between December 2020 and March 2022 at the Yaoundé General Hospital (HGY) and the University Teaching Hospital of Yaounde (UTHY).

Seroprevalence of Epstein-Barr virus, hepatitis B virus, hepatitis C virus, and human immunodeficiency virus among patients with non-Hodgkin's lymphoma at the Yaounde General Hospital, Cameroon.

The non-Hodgkin's lymphomas (NHLs) are a diverse group of malignancies that originate in lymphoid cells, heterogeneous in clinical behavior, morphology, cellular origin, etiology, and pathogenesis. A viral infectious etiology had been associated with them. This study aimed to investigate the seroprevalence of Epstein-Barr virus (EBV), Hepatitis B virus (HBV), Hepatitis C virus (HCV) and Human Immunodeficiency Virus (HIV) among patients with NHL at the Yaoundé General Hospital (YGH).